Caroline Leibowitz
Family · Oakhurst, NJNPI 1114532173
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.9% of the total across 609 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 17.4% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $3,790, 5.7 times the $668 reported in 2021. Among family clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 609 payments — averaging $16.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$981
- Johnson & Johnson$959
- Pfizer$725
- Amgen$481
- plus $4K from 33 others
What the payments were for
- Food & beverage$9,99299%
- Education$1061%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 97 | $1,754 |
| Takeda Pharmaceuticals U.S.A., Inc. | 67 | $1,121 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 61 | $981 |
| Johnson & Johnson(2 entities) | 55 | $959 |
| Pfizer | 42 | $725 |
| Amgen | 10 | $481 |
| Bristol Myers Squibb | 26 | $378 |
| Lilly USA, LLC | 26 | $378 |
| Madrigal Pharmaceuticals | 28 | $334 |
| Sanofi | 16 | $292 |
| QOL Medical, LLC | 15 | $283 |
| Ardelyx, Inc. | 15 | $269 |
| Daiichi Sankyo Inc. | 14 | $217 |
| Aimmune Therapeutics, Inc. | 37 | $206 |
| GSK | 12 | $185 |
| Novo Nordisk | 11 | $155 |
| Boehringer Ingelheim | 3 | $128 |
| AstraZeneca | 1 | $125 |
| Ferring Pharmaceuticals Inc. | 8 | $120 |
| Ipsen Biopharmaceuticals, Inc | 6 | $113 |
| Gilead | 7 | $111 |
| Regeneron Healthcare Solutions, Inc. | 6 | $107 |
| Celltrion USA Inc. | 6 | $99 |
| Sanofi-aventis U.S. LLC | 6 | $85 |
| Phathom Pharmaceuticals, Inc. | 7 | $69 |
| Nestle Healthcare Nutrition Inc. | 4 | $64 |
| Intercept Pharmaceuticals, Inc. | 3 | $45 |
| Intra-sana Laboratories | 3 | $44 |
| Amarin Pharma, Inc. | 3 | $41 |
| Merck | 2 | $38 |
| Braintree Laboratories, Inc. | 2 | $33 |
| Eisai Inc. | 2 | $30 |
| Organon | 2 | $29 |
| Sandoz | 1 | $25 |
| Evoke Pharma, Inc. | 1 | $18 |
| Fresenius Kabi USA, LLC | 1 | $16 |
| Mallinckrodt Hospital Products Inc. | 1 | $15 |
| Genentech USA, Inc. | 1 | $14 |
| Jazz Pharmaceuticals Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,098 in reported general payments places this provider in the 95th percentile of 2,692 family providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 12 | $318,663 |
| RinvoqUpadacitinib | 13 | $102,943 |
| CreonLipase/Protease/Amylase | 17 | $38,644 |
| XifaxanRifaximin | 14 | $30,722 |
| LinzessLinaclotide | 30 | $23,540 |
| Dexlansoprazole DrDexlansoprazole | 14 | $3,678 |
| PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C | 22 | $2,976 |
| Lubiprostone | 13 | $2,934 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 17 | $2,732 |
| Pantoprazole Sodium | 135 | $2,348 |
| Sucralfate | 12 | $2,265 |
| Esomeprazole Magnesium | 38 | $966 |
| Omeprazole | 110 | $907 |
| Famotidine | 91 | $889 |
| Hydrocortisone | 33 | $539 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $959 | $318,66312 claims |
| AbbVieRinvoq, Creon, Linzess | $1,754 | $165,12760 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Plenvu | $981 | $33,69836 claims |
| Braintree Laboratories, Inc.Sutab | $33 | $2,73217 claims |
| SandozLansoprazole | $25 | $45821 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,692 family providers in New Jersey.
Other family in Oakhurst
- Aileen Joanna Almeda VasquezOakhurst$9K
- Jennifer DemaioMorristown$412K
- Kara TrlicaCranbury$186K
- Nicole BauerParamus$161K
- China BattistaWall Township$142K
- Nancy EisenbergerVoorhees$82K
- Jennifer AbitabiloGlen Ridge$54K
- Megan FiloramoMorristown$53K
- Shawn DenningToms River$29K
- Kimberly ClementeEatontown$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.